The Brazilian Government announced on 9 February 2014 that it is setting up a committee to evaluate whether to exempt medicines from tax in the country.
Proposal in Brazil to exempt medicines from tax
Home/Policies & Legislation
|
Posted 21/03/2014
0
Post your comment

The joint committee will be set up in order to speed up the analysis process and provide an answer on the Proposal (PEC 301/13), which would ban taxes on pharmaceutical drugs and ingredients used in production and marketing.
The proposal on tax exemption of medicines was organized by the Parliamentary Front for the Tax Exemption of Medicines, with the campaign being organized by the Brazilian Association of Pharmacies and Drugstores Networks (Abrafarma) in partnership with the Association of Pharmaceutical Industry Research (Interfarma).
The proposal was introduced to the Brazilian House of Representative as a constitutional amendment, by Mr Francisco Chagas. The following arguments have been stated as reasons for the introduction of this proposal:
• To put an end to different tax rates on pharmaceuticals between different states in Brazil
• To encourage the creation of an industrial policy to strengthen the pharmaceutical sector in Brazil (national production is currently less than 10%)
• To generate technology, jobs and investment
• To provide savings to patients when buying medicines, estimated at BRL 19 billion
Taxes on pharmaceuticals in Brazil are currently estimated by Abrafarma and Interfarma to be around 33.9%, which represents more than a third of the final price paid by consumers.
Related articles
Confusion exists in Brazil over generics
Brazil to designate medicamentos similares as interchangeable
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Reports
FTC reveals extent of PBM drug mark-ups and profits
Latin American patients face 4.7-year wait for innovative treatments
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
NPRA Malaysia trials new timelines for variation applications

Home/Policies & Legislation Posted 05/11/2024
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US

Home/Policies & Legislation Posted 18/09/2024
China’s NMPA expands global ties with the Netherlands and Indonesia

Home/Policies & Legislation Posted 04/09/2024
Japan's PMDA expands influence with new office in Thailand

Home/Policies & Legislation Posted 06/08/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment